Eli Lilly and Company to Acquire Mablink Bioscience

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

Genmab to Acquire ProfoundBio for $1.8 Billion

April 3, 2024

Biotechnology

Genmab (Nasdaq: GMAB) and ProfoundBio announced a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction valued at $1.8 billion. The deal will expand Genmab’s mid- to late-stage oncology pipeline by adding ProfoundBio’s next-generation antibody-drug conjugate (ADC) programs, including Rina-S.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Eli Lilly and Company Acquires Disarm Therapeutics

October 15, 2020

Biotechnology

Eli Lilly and Company agreed to acquire Cambridge-based Disarm Therapeutics for an upfront $135.0 million, with potential development, regulatory and commercial milestone payments of up to $1.225 billion. The acquisition adds Disarm's preclinical SARM1 inhibitor programs to Lilly's R&D efforts in pain and neurodegeneration to accelerate development of disease‑modifying therapies for axonal degeneration.

Sterling Pharma Solutions Acquires ADC Biotechnology

April 7, 2021

Biotechnology

Sterling Pharma Solutions, a GHO Capital portfolio CDMO, has acquired ADC Biotechnology (ADC Bio), a Deeside-based bioconjugation and ADC development services business. The deal adds ADC capabilities and a Deeside facility to Sterling’s international network and includes multi-million pound investment to grow bioconjugation, analytical and cGMP ADC manufacturing capabilities.

Omnicell Acquires Pharmaceutical Strategies Group's 340B Link Business from Blue Wolf Capital

October 2, 2020

Healthcare Services

Omnicell, Inc. has acquired Pharmaceutical Strategies Group's market-leading 340B Link business from Blue Wolf Capital Partners for $225 million. The deal, which completes Blue Wolf's exit of PSG from Fund II, expands Omnicell's medication management and data-enabled services for hospitals and pharmacies.